Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor (EGFR) Protein Overexpression”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Testing effectiveness (Phase 2)Study completedNCT00258960
What this trial is testing

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 49
Early research (Phase 1)Ended earlyNCT00251433
What this trial is testing

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 53
Early research (Phase 1)Looking for participantsNCT04686305
What this trial is testing

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 304
Early research (Phase 1)Study completedNCT03234712
What this trial is testing

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Who this might be right for
Advanced Solid Tumors Cancer
AbbVie 62
Testing effectiveness (Phase 2)Study completedNCT02205047
What this trial is testing

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Malignant Neoplasm of StomachMalignant Neoplasm of Cardio-esophageal Junction of StomachEpidermal Growth Factor Receptor (EGFR) Protein Overexpression
European Organisation for Research and Treatment of Cancer - EORTC 172
Testing effectiveness (Phase 2)Looking for participantsNCT02861898
What this trial is testing

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

Who this might be right for
GlioblastomaBrain CancerBrain Neoplasm+4 more
Northwell Health 33
Testing effectiveness (Phase 2)Looking for participantsNCT07712029
What this trial is testing

Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive

Who this might be right for
Advanced Refractory Solid TumorsEGFR Gene Overexpression
Tianjin Medical University Second Hospital 32
Testing effectiveness (Phase 2)WithdrawnNCT05512182
What this trial is testing

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Who this might be right for
Recurrent/Advanced Gastric Cancer
Yonsei University
Not applicableUnknownNCT02136836
What this trial is testing

Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer

Who this might be right for
Stomach Neoplasms
Yonsei University 860
Testing effectiveness (Phase 2)Study completedNCT03329690
What this trial is testing

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Who this might be right for
Neoplasm, Gastrointestinal
Daiichi Sankyo Co., Ltd. 233
Testing effectiveness (Phase 2)Study completedNCT00294762
What this trial is testing

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
OSI Pharmaceuticals 143
Large-scale testing (Phase 3)Study completedNCT00281658
What this trial is testing

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 444